Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Symptomatic hyponatraemia caused by cylophosphamide.
Berger AK, Bellos F, Siegmund A, Eisenbach C, Lordick F. Berger AK, et al. Onkologie. 2009 May;32(5):280-2. doi: 10.1159/000209292. Epub 2009 Apr 3. Onkologie. 2009. PMID: 19420976
A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jäger D. Berger AK, et al. BMC Cancer. 2012 Mar 22;12:108. doi: 10.1186/1471-2407-12-108. BMC Cancer. 2012. PMID: 22439666 Free PMC article. Clinical Trial.
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
Berger AK, Lücke S, Abel U, Haag GM, Grüllich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jäger D. Berger AK, et al. Br J Cancer. 2018 Jul;119(2):170-175. doi: 10.1038/s41416-018-0152-4. Epub 2018 Jul 2. Br J Cancer. 2018. PMID: 29961759 Free PMC article. Clinical Trial.
Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
Olkus A, Tomczak A, Berger AK, Rauber C, Puchas P, Wehling C, Longerich T, Mehrabi A, Chang DH, Liermann J, Schäfer S, Pfeiffenberger J, Jäger D, Michl P, Springfeld C, Dill MT. Olkus A, et al. Among authors: berger ak. Target Oncol. 2024 Mar;19(2):213-221. doi: 10.1007/s11523-024-01044-1. Epub 2024 Feb 28. Target Oncol. 2024. PMID: 38416377 Free PMC article.
136 results